2-(4-甲氧基-3-甲基苯基)乙醇 | 87776-77-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 2-(4-甲氧基-3-甲基苯基)乙醇
• 英文名称: 4-Methoxy-3-methyl-phenethylalkohol
• 英文别名: 2-(4-methoxy-3-methylphenyl)ethanol
• CAS: 87776-77-0
• 化学式: C₁₀H₁₄O₂
• 分子量: 166.22
• InChiKey: PWCJNLPJZLJFPT-UHFFFAOYSA-N

物化性质

• 熔点：
  45-46 °C
• 沸点：
  120 °C(Press: 8 Torr)
• 密度：
  1.038±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2909499000

反应信息

• 作为反应物：
  描述：

  2-(4-甲氧基-3-甲基苯基)乙醇 在 sodium 、 三溴化磷 作用下， 以 四氯化碳 、 乙醇 为溶剂， 生成 5-Oxo-8-(4-methoxy-3-methyl-phenyl)-octansaeure
  参考文献：
  名称：

  Nasipuri,D.; Roy,D.N., Journal of the Indian Chemical Society, 1963, vol. 40, # 5, p. 327 - 338

  摘要：

  DOI：
• 作为产物：
  描述：

  tert-butyl(4-methoxy-3-methylphenethoxy)dimethylsilane 在 2,6-disulphated cellulose 作用下， 以 甲醇 为溶剂， 反应 0.33h， 以90%的产率得到2-(4-甲氧基-3-甲基苯基)乙醇
  参考文献：
  名称：

  高度硫酸化的纤维素：一种多功能的，可重复使用的，选择性的甲硅烷基化剂，用于脱醇TBDMS醚

  摘要：

  开发了一种温和，有效和快速的方案，使用可回收的，环境友好的高度硫酸化的硫酸纤维素硫酸酯催化剂在甲醇中脱醇TBDMS醚。该酸催化剂在含有醇和酚TBDMS醚部分的双-TBDMS醚中选择性裂解醇TBDMS醚。

  DOI：

  10.1039/c8ob01438h

文献信息

• 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle
  申请人：Sekiguchi Yoshinori

  公开号：US20080318923A1

  公开（公告）日：2008-12-25

  It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

  旨在提供一种对与精氨酸加压素V1b受体相关的病理状况具有疗效的药物。更具体地说，旨在提供一种对抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、消化系统疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫疾病、脱发等具有治疗或预防作用的药物。经过深入研究，发现了一种新颖的1,3-二氢-2H-吲哚-2-酮化合物和与杂芳环融合的吡咯烷-2-酮化合物，它们是高度选择性的精氨酸加压素V1b受体拮抗剂，具有高代谢稳定性，表现出有利的血脑屏障穿透和高血浆浓度，从而实现了上述目标。
• [EN] CYCLIC AMINE SUBSTITUTED OXAZOLIDINONE CETP INHIBITOR<br/>[FR] INHIBITEUR DE CETP SUBSTITUÉ PAR DES AMINES CYCLIQUES À BASE D'OXAZOLIDINONE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012058187A1

  公开（公告）日：2012-05-03

  CCompounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A3 is a substitiuted phenyl group or indanyl group.Formula (I).

  具有公式I结构的化合物，包括这些化合物的药用盐，是CETP抑制剂，可用于提高HDL胆固醇，降低LDL胆固醇，并用于治疗或预防动脉粥样硬化。在公式I的化合物中，A3是一个取代苯基或茚基。公式（I）。
• Sphingosine-1-phosphate receptor agonist and antagonist compounds
  申请人：Wallace Grier A.

  公开号：US20090029947A1

  公开（公告）日：2009-01-29

  The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.

  本发明涉及一种新型、有效和选择性的药剂，它们是S1P受体家族中一个或多个单个受体的激动剂或拮抗剂。本发明的化合物可用作治疗与S1P受体家族中单个受体的激动或拮抗有关的医学状况的治疗剂。
• WO2008/79382
  申请人：——

  公开号：——

  公开（公告）日：——
• Structural Modifications to Tetrahydropyridine-3-carboxylate Esters en Route to the Discovery of M₅-Preferring Muscarinic Receptor Orthosteric Antagonists
  作者：Guangrong Zheng、Andrew M. Smith、Xiaoqin Huang、Karunai L. Subramanian、Kiran B. Siripurapu、Agripina Deaciuc、Chang-Guo Zhan、Linda P. Dwoskin

  DOI：10.1021/jm301774u

  日期：2013.2.28

  The M-5 muscarinic acetylcholine receptor is suggested to be a potential pharmacotherapeutic target for the treatment of drug abuse. We describe herein the discovery of a series of M-5-preferring orthosteric antagonists based on the scaffold of 1,2,5,6-tetrahydropyridine-3-carboxylic acid. Compound 56, the most selective compound in this series, possesses an 11-fold selectivity for the M-5 over M-1 receptor and shows little activity at M-2-M-4. This compound, although exhibiting modest affinity (K-i = 2.24 mu M) for the [H-3]N-methylscopolamine binding site on the M-5 receptor, is potent (IC50 = 0.45 nM) in inhibiting oxotremorine-evoked [H-3]DA release from rat striatal slices. Further, a homology model of human M-5 receptor based on the crystal structure of the rat M-3 receptor was constructed, and docking studies of compounds 28 and 56 were performed in an attempt to understand the possible binding mode of these novel analogues to the receptor.